Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:CCELNASDAQ:EUDANASDAQ:NAKANASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCELCryo-Cell International$5.43+7.1%$5.14$4.75▼$9.43$40.98M0.6612,957 shs146,796 shsEUDAEUDA Health$3.58-2.2%$3.71$2.92▼$6.30$135.99M-0.0383,838 shs105,406 shsNAKAKindlyMD$14.68+4.0%$0.00$0.65▼$34.77$85.14MN/A979,556 shs277,941 shsXGNExagen$6.99+3.2%$6.51$1.71▼$7.95$144.20M1.6132,951 shs146,303 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCELCryo-Cell International+7.10%+5.64%+11.50%-13.81%+3.23%EUDAEUDA Health-2.19%-4.02%-0.83%-2.19%-5.54%NAKAKindlyMD+3.97%+5.31%+1,467,999,900.00%+1,467,999,900.00%+1,467,999,900.00%XGNExagen+3.25%-5.03%+2.64%+82.03%+275.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCELCryo-Cell International2.1116 of 5 stars3.53.01.70.00.01.70.0EUDAEUDA Health0.3814 of 5 stars0.03.00.00.02.00.00.6NAKAKindlyMDN/AN/AN/AN/AN/AN/AN/AN/AXGNExagen3.2097 of 5 stars1.53.00.04.51.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCELCryo-Cell International 3.00Buy$8.5056.54% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/ANAKAKindlyMD 0.00N/AN/AN/AXGNExagen 3.00Buy$7.507.30% UpsideCurrent Analyst Ratings BreakdownLatest CCEL, XGN, EUDA, and NAKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCELCryo-Cell International$31.99M1.37$0.19 per share28.29($1.64) per share-3.31EUDAEUDA Health$4.01M33.18N/AN/A($0.07) per share-51.14NAKAKindlyMD$2.72M32.54N/AN/A$0.43 per share34.14XGNExagen$55.64M2.68N/AN/A$0.54 per share12.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCELCryo-Cell International$400K-$1.06543.54∞N/A0.40%-1.07%0.20%N/AEUDAEUDA Health-$15.36MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)NAKAKindlyMD-$3.62M-$0.77N/A∞N/A-177.01%-146.26%-109.19%N/AXGNExagen-$15.11M-$0.84N/AN/AN/A-27.34%-133.69%-34.87%8/4/2025 (Estimated)Latest CCEL, XGN, EUDA, and NAKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCELCryo-Cell International$0.6011.05%N/AN/A N/AEUDAEUDA HealthN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ALatest CCEL, XGN, EUDA, and NAKA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/8/2025CCELCryo-Cell Internationalquarterly$0.1511.79%5/21/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCELCryo-Cell InternationalN/A0.580.54EUDAEUDA HealthN/A0.180.15NAKAKindlyMDN/A2.302.30XGNExagen2.872.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCELCryo-Cell International10.44%EUDAEUDA Health4.35%NAKAKindlyMDN/AXGNExagen75.25%Insider OwnershipCompanyInsider OwnershipCCELCryo-Cell International36.86%EUDAEUDA HealthN/ANAKAKindlyMD50.50%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCELCryo-Cell International908.08 million5.10 millionNot OptionableEUDAEUDA Health237.16 millionN/ANot OptionableNAKAKindlyMDN/A6.03 million2.99 millionN/AXGNExagen22021.30 million18.62 millionOptionableCCEL, XGN, EUDA, and NAKA HeadlinesRecent News About These Companies2025-06-23 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics | NDAQ:XGN | Press Release - StockhouseJune 24 at 10:14 PM | stockhouse.comMichael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune DiagnosticsJune 23, 2025 | globenewswire.comExagen announces resale of up to 1.15M sharesJune 20, 2025 | msn.comCantor Fitzgerald Estimates Exagen FY2026 EarningsJune 13, 2025 | marketbeat.comExagen Inc. Holds 2025 Annual Stockholder MeetingJune 11, 2025 | tipranks.comToronto Dominion Bank Buys New Position in Exagen Inc. (NASDAQ:XGN)June 1, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateJune 1, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call TranscriptMay 11, 2025 | insidermonkey.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional SharesMay 9, 2025 | finance.yahoo.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesMay 9, 2025 | globenewswire.comExagen Inc. Prices Public Offering of Common StockMay 8, 2025 | globenewswire.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comExagen Inc. Announces Proposed Public Offering of Common StockMay 7, 2025 | globenewswire.comEarnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dipsMay 6, 2025 | uk.investing.comExagen Inc. Reports Record Revenue Amid Strategic GrowthMay 5, 2025 | tipranks.comExagen Inc. Earnings Call Highlights Record GrowthMay 5, 2025 | tipranks.comExagen Inc. (XGN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comExagen Inc. (XGN) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2025 | zacks.comExagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing VolumeMay 5, 2025 | globenewswire.comExagen Inc (XGN) Q1 2025 Earnings Report Preview: What To ExpectMay 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedGovernment Mandate Sends eVTOL Stocks FlyingBy Jeffrey Neal Johnson | June 10, 2025View Government Mandate Sends eVTOL Stocks FlyingAMD Accelerates Stack Development: Share Price to FollowBy Thomas Hughes | June 16, 2025View AMD Accelerates Stack Development: Share Price to FollowOracle Stock Boils Higher, $300 Price Target in SightBy Thomas Hughes | June 25, 2025View Oracle Stock Boils Higher, $300 Price Target in SightCCEL, XGN, EUDA, and NAKA Company DescriptionsCryo-Cell International NYSEAMERICAN:CCEL$5.43 +0.36 (+7.10%) Closing price 06/26/2025 04:10 PM EasternExtended Trading$5.40 -0.03 (-0.63%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.EUDA Health NASDAQ:EUDA$3.58 -0.08 (-2.19%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$3.70 +0.12 (+3.35%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.KindlyMD NASDAQ:NAKA$14.68 +0.56 (+3.97%) As of 06/26/2025 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.Exagen NASDAQ:XGN$6.99 +0.22 (+3.25%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$6.94 -0.05 (-0.72%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
